Navigation Links
Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference
Date:8/8/2014

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34th Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET).

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring.  Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2014, more than 19,000 physicians in over 70 countries had ordered more than 465,000 Oncotype DX tests.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2014. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014
2. QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline
3. Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery
4. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
5. Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
8. Strand Life Sciences to Partner with US Based El Camino Hospital to Set Up Strand Center for Genomics and Personalized Medicine
9. Gentris Corporation Opens New Genomic Biomarker Laboratory in China
10. Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials
11. Genomic Health Announces Third Quarter 2013 Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/10/2017)... 10, 2017 Hologic, Inc. (Nasdaq: ... the fiscal second quarter ended April 1, 2017 . ... increased 666.7% compared to the prior year period as ... a significant gain, while non-GAAP diluted EPS of $0.50 ... 3.8% in constant currency terms.  Excluding the effects of ...
(Date:5/9/2017)... May 9, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, today announced it has earned a spot on ... list. The Company was ranked among 500 U.S. employers ... and Healthcare Equipment and Services. The annual ... an anonymous, independent survey of over 30,000 employees across ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... continue to be available at a discounted crowdfunding price on Indiegogo . , ... are, I also wanted to bring a fidget toy to the market that was ...
(Date:5/26/2017)... ... ... Silver Birch of Hammond, a new assisted lifestyle community, has welcomed its first ... at 5620 Sohl Avenue in Hammond, serves older adults who need some help to ... apartments. Each of the private apartments at Silver Birch features a kitchenette, spacious bathroom ...
(Date:5/26/2017)... ... , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in wisdom teeth ... insurance options. If a Bay Area patient has to search for a second opinion ... an in-network provider for a second opinion can ensure a patient receives the full ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the ... Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... to say, he is "panther quick and leather tough." His love for others is ...
Breaking Medicine News(10 mins):